Bavarian Nordic, Inc.

First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa impacted by the mpox outbreak. Under the agreement, UNICEF will procure 1 million doses of the vaccine which includes the 500,000 doses that were committed by Gavi and announced on September 18, 2024. As part of Bavarian Nordics commitment to increase and prioritize its production capacity to fulfil the short- and medium-term demand, the Company will make all doses available for supply before the end of 2024 and will work with UNICEF and its partners to swiftly deliver the vaccines upon request. Paul Chaplin, President & CEO of Bavarian Nordic, said: “The agreement with UNICEF represents a significant contribution to the global efforts to combat the mpox outbreak in Africa and we are proud to assist with making our vaccine rapidly available to help where they are needed. Combined with donations by various governments, institutions and Bavarian Nordic, this agreement has helped to secure more than 2.5 million doses of MVA-BN, thus fulfilling the short-term requirement as expressed by the Africa CDC. This is a huge milestone to achieve within such a short timeframe and we applaud UNICEF, Gavi and their partners along with nations who have contributed with donations for their commitments to make this happen. We will continue our efforts together with partners to secure the necessary availability of vaccines beyond 2024.” About the mpox vaccineMVA-BN or Modified Vaccinia Ankara-Bavarian Nordic is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS®), Canada (marketed as IMVAMUNE®), and the EU/EAA and United Kingdom (marketed as IMVANEX®). Originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines, MVA-BN has been indicated for use in the general adult population in individuals considered at risk for smallpox or mpox infection. In the EU/EAA, the vaccine has also been approved for adolescents 12-17 years of age. Bavarian Nordic has been a long-term supplier of the vaccine to a number of nations, and during the 2022-2023 mpox outbreak, the Company supported governments and supranational organizations by expanding access to the vaccine to more than 70 countries worldwide. About Bavarian NordicBavarian Nordic is a fully integrated vaccine company with a mission to protect and save lives through innovative vaccines. We are a global leader in smallpox and mpox vaccines, supplied to governments to enhance public health preparedness and have a strong portfolio of vaccines for travelers and endemic diseases. For more information visit www.bavarian-nordic.com. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. ContactsEurope: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 Company Announcement no. 33 / 2024 Attachment 2024-33-en

Pictured: Syringe drawing up vaccine/iStock, Diy13 The competitive race to develop an effective chikungunya vaccine is heating up, after Danish biotech Bavarian Nordic posted positive Phase III results for its vaccine candidate—the second late-stage trial data in as many months. The latest results from Bavarian Nordic’s study of over 3,500 patients found that its virus-like particle (VLP)-based candidate produced strong induction of chikungunya-inducing antibodies in 98% of those who had received the vaccine versus placebo. In addition, 97% of subjects had antibodies induced within two weeks of vaccination “confirming a rapid onset of protective levels of immunity,” the company said in a statement. Bavarian Nordic also noted that the vaccine was “well-tolerated in this adolescent and adult population and adverse events were mainly mild or moderate in nature.” The positive results follow good news from Bavarian Nordic in June, when the company posted similar Phase III study results for an older population. While those results were not as strong, they nevertheless showed chikungunya-neutralizing antibodies in 87% of participants within three weeks of vaccination after a single vaccination, which were also “well-tolerated,” Nordic said. The race to develop an effective chikungunya vaccine has been heating up. French biotech Valneva reported promising Phase III results around the same time Nordic was posting its results in elderly patients. The Valneva study, published in The Lancet, found its vaccine had a 28-day seroprotection rate of 98.9%. In patients aged 18-64, the seroprotection rate was 98.6% and patients aged 65 or older had a 100% seroprotection rate. The study also noted that more than half of patients given the vaccine experienced an adverse event, with two serious adverse events were deemed to be related to it. Valneva’s vaccine was submitted to the FDA’s rolling submissions, which the regulator gave Priority Review, with a decision expected this month. Bavarian Nordic, for its part, will be using the results from its two latest studies to support applications to both the FDA and the European Medicines Agency. “With a fast and durable response, our vaccine has the potential to be the best in class to prevent chikungunya infections in adolescents to elderly adults," Bavarian Nordic CEO Paul Chaplin said in a statement, noting that the company’s “focus remains to finalize the studies and prepare for regulatory submissions next year.” However, the field is less crowded after Merck dropped out of the vaccine race in February, as reported by Fierce Biotech. The decision was made as part “routine pipeline prioritization,” according to a company spokesperson. While serious symptoms and death are rare, chikungunya is a widespread disease present in over 110 countries and there is currently no vaccine, according to the World Health Organization. However, the disease has high morbidity and, consequently, a heavy economic and healthcare burden. Caused by a Togaviridae virus carried by Aedes Aegypti mosquitos, chikungunya causes symptomatic infection in up to 92% of infected humans. Connor Lynch is a freelance writer based in Ottawa, Canada. Reach him at lynchjourno@gmail.com.

COPENHAGEN, Denmark, September 2, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the dosing of the first subject in the Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate. The double-blind, controlled Phase 3 clinical trial will enroll approximately 4,000 adult subjects who either previously completed primary vaccination or have already received one booster dose of a licensed COVID-19 vaccine. The trial consists of two groups. An active controlled group will be conducted in Denmark and Belgium and will start enrollment later this fall. Subjects in this group will be randomized to receive either a single 100 µg dose of ABNCoV2, or a single 30 µg adult booster dose of Comirnaty. The second group, which has now started enrollment in the U.S., will evaluate the safety and tolerability of the vaccine in subjects receiving a single 100 µg dose of ABNCoV2. Initial trial results are expected towards the end of 2022, which will allow for a rolling submission to the regulatory authorities, aiming to obtain approval of the vaccine in 2023. Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic, said: “Advancing ABNCoV2 into Phase 3 trials represents another significant step in the progression of our pipeline this year, and not least an important contribution to the development of a universal COVID-19 booster vaccine. In clinical trials to-date, ABNCoV2 has shown potential to boost neutralizing antibodies against SARS-CoV-2, including variants of concern, to levels associated with a high degree of protection. We hope that the Phase 3 trial will confirm these strong results, thus unleashing the potential of ABNCoV2 as a differentiated approach without the need for adaptation”. The Phase 3 development of ABNCoV2 is partly funded through an agreement with the Danish State. About ABNCoV2 ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark, using their proprietary capsid virus like particle (cVLP) technology. Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure. ABNCoV2 has shown to be highly immunogenic in relevant preclinical models inducing a durable and highly protective response from a COVID-19 challenge. Results from a Phase 2 trial has confirmed the ability of ABNCoV2 to significantly boost antibody titers as previously demonstrated in preclinical and Phase 1 clinical trials, and also confirm the potential of ABNCoV2 to boost antibody titers against SARS-CoV2 variants of concern. About Bavarian Nordic Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.